

Press release
26 April 2026

Major Shareholding Notification - share transfer and ownership restructuring – related party transaction

Copenhagen, 26 April 2026 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) announces that the company has received notification that AK 2014 Holding ApS, Krasilnikoff Holding ApS and UK Curacap ApS have merged their holding of shares in Curacap II ApS. This announcement is published in accordance with the applicable major shareholding notification rules of Spotlight Stock Market.

Background

It is hereby announced that a change in the shareholding structure of a technical nature has been completed following an internal restructuring between existing major shareholders.

Co-founder, CMO & CSO Andreas Kjær and CEO & CFO Ulrich Krasilnikoff have implemented a consolidation of their ownership into a jointly controlled holding structure. As part of the transaction, shares previously held by Andreas Kjær through AK 2014 Holding ApS, as well as shares previously held by Ulrich Krasilnikoff through UK Curacap ApS, have been contributed to a jointly owned company Curacap II ApS by way of a share-for-share exchange.

The restructuring is of a technical nature and does not result in any change in ultimate control, voting power, or beneficial ownership at the individual level. The purpose of the transaction is to simplify and streamline the founder ownership structure.

Transaction Details

AK 2014 Holding ApS wholly owned company by Andreas Kjær will transfer all of its shares (7,365,145 equal to 15.23%) in Curasight A/S to Curacap II ApS. UK Curacap ApS owned by Ulrich Krasilnikoff, Susanne Krasilnikoff and Peter Krasilnikoff will transfer all of its shares (5,329,856 equal to 11.03%) to Curacap II ApS. At the same time Krasilnikoff Holding ApS (owned by Peter Krasilnikoff) have contributed 1,000,000 shares to Curacap II ApS by way of a share-for-share exchange.

Following completion:

- AK 2014 Holding ApS holds 53.78% of Curacap II ApS
- Krasilnikoff Holding 1 ApS holds 25.95% of Curacap II ApS
- Krasilnikoff Holding ApS holds 20.27% of Curacap II ApS

Curacap II ApS will, following the transaction, hold 13,695,001 shares in Curasight A/S, corresponding to approximately 28.33% of the shares and voting rights.

Governance Arrangements

Curacap II ApS is jointly owned, governed and controlled by Andreas Kjær and Ulrich Krasilnikoff. The shareholders have agreed that all material decisions in Curacap II ApS shall be made unanimously between Andreas Kjær and Ulrich Krasilnikoff. Both parties have equal influence over decisions affecting their combined shareholding in the Company. In the event of disagreements each party can require that Curacap II ApS is liquidated.



PROVIDING ANSWERS FOR CANCER PATIENTS

The transaction constitutes a crossing of the relevant flagging thresholds pursuant to the Spotlight Stock Market Rulebook, Section 4.21. In accordance with these rules, the Company is required to inform the market when a shareholder's holding exceeds or falls below specified thresholds, including 25% and 30%. As a result of the transaction, the shareholding has exceeded the 25% threshold.

The transaction has been completed, and this announcement is made in compliance with applicable rules.

Impact on the Company

The reorganisation is a matter between the shareholders and does not affect the Company's operations, strategy, or financial position. The Company notes that the assessment of whether the transaction also constitutes a notifiable transaction under Danish law is subject to confirmation with the Danish Financial Supervisory Authority.

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60

E-mail: uk@curasight.com

www.curasight.com

Curasight is a clinical-stage radiopharmaceutical company pioneering a uPAR-targeted theranostic platform that combines precision diagnostic imaging (uTRACE®) with 100% corresponding targeted radioligand therapy (uTREAT®). Curasight is pioneering first-in-class radioligand therapy targeting uPAR – the pan-tumor functional driver of invasion, angiogenesis, and metastasis. By selectively targeting the biological drivers of cancer invasion, angiogenesis and metastasis, our approach enables personalized, pan-tumor treatment with the ambition to improve outcomes across aggressive solid tumors.